For patients with obesity, clinicians should move beyond a "try and fail" approach to lifestyle interventions and prioritize ...

For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7% on average.

With semaglutide and tirzepatide dosed once weekly, their estimated average yearly costs in the U.S. are $14,080 and $8,126, ...

In the context of new anti-obesity medications, the American College of Cardiology has issued a Scientific Statement updating ...

GPs will be allowed to prescribe weight loss jabs for the first time from Monday. The mass rollout will see around 220,000 ...

"According to our data, this could be explained by higher rates of discontinuation and lower maintenance dosages used in clinical practice." HealthDay News — For patients with obesity initiating ...

The researchers found that at 1 year, the mean percentage weight reduction was 8.7% for patients receiving semaglutide and tirzepatide. HealthDay News — For patients with obesity initiating ...

Q: My doctor is suggesting that I try taking one of those new weight loss drugs -- off-label -- to help me cut down on my alcohol consumption. Does this make any sense? -- Pat R., Ann Arbor, Michigan ...

In real-world cohort, percentage weight reduction at one year was 3.6, 6.8, and 11.9 percent with early and late discontinuation and nondiscontinuation, respectively. (HealthDay News) — For ...

A new study reports that people taking GLP-1 drugs in daily life don’t lose as much weight as those in clinical trials who ...

Researchers compared the safety and efficacy of tirzepatide (brand name Zepbound) and semaglutide (brand name Wegovy) in a 72-week clinical trial. The randomized, controlled trial — called ...

The American College of Cardiology has issued new guidelines recommending weight management medications as first-line ...